The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

Bernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

Pfizer will also have the option of commercialization rights in China. Under the agreement, 3SBio will receive an ... this site does not imply any form of partnership, agency, or endorsement.

The deal, which excludes China but provides Pfizer with an option for commercialization rights within the country, involves an upfront payment of $1.25 billion to 3SBio.

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

Vohra Wound Physicians Management, LLC, Dr. Ameet Vohra, and VHS Holdings, P.A. filed a Motion to Dismiss in the United States District Court for the Southern District of Florida in Case No.

Kaneka North America LLC Nutrients Division ("Kaneka Nutrients") has initiated comprehensive efforts to identify and expose misleading claims about ubiquinol in response to an increasing number of ...